Biden's prostate cancer diagnosis highlights need for screenings, survivors and experts say
Biden, 82, is reportedly in good spirits following the announcement, though his office confirmed that the cancer has spread to his bones.
Doctors say that while late-stage diagnoses are more difficult to treat, early detection dramatically improves survival rates.
Former President Biden diagnosed with aggressive form of prostate cancer
'It was a complete shock,' retired U.S. Army Colonel Jim Williams, a prostate cancer survivor said. 'A young doctor arbitrarily included a PSA in my bloodwork—and that's how we caught it.'
The PSA, or prostate-specific antigen test, is one of the most common ways prostate cancer is detected.
According to CARTI, an Arkansas-based cancer treatment center, nearly one in eight American men will be diagnosed with prostate cancer in their lifetime.
Williams, now more than 30 years cancer-free, credits not just the PSA test, but also a digital rectal exam with helping detect his cancer early.
Biden diagnosed with prostate cancer: What is it?
'Prostate cancer typically is one of these cancers that is asymptomatic for quite a while, until it becomes more advanced,' Dr. Matthew Hardee said. 'That's why screenings are so important.'
Hardee explained that men without a family history should begin routine screenings between the ages of 55 and 70, a relatively narrow window. Biden, at 82, is past that range.
Still, Hardee emphasized that treatment options for prostate cancer have expanded in recent years—even for cases that have metastasized.
'There are many more options now than ever before,' he said. 'Even in situations like President Biden's, where the cancer has spread, there's still hope and a lot of ways to manage the disease.'
Biden's sudden diagnosis of aggressive prostate cancer is unfortunately all too common
Prostate cancers are assigned a Gleason score from 1 to 10, indicating how abnormal the cancer cells appear under a microscope. Biden's office confirmed his score was 9, signaling an aggressive form of the disease.
Doctors and survivors alike are urging men not to wait for symptoms, which may not appear until the cancer is advanced. With regular screening and early intervention, many cases can be treated successfully.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
27 minutes ago
- The Hill
Most adults do not plan on getting COVID-19 shot amid vaccine policy changes
More than half of American adults — 59 percent — say they do not expect to get the COVID-19 booster shot this autumn, according to new poll findings from healthcare policy group KFF. Poll results show that 23 percent of U.S. adults say they will 'probably not' get the vaccine, while 37 percent will 'definitely not' get the shot. Americans who said they will 'probably' or 'definitely' not get the shot were also more likely to say they think changes to U.S. vaccine policy are 'major' and will make people less safe. The data comes as the Trump administration makes drastic changes to the country's vaccine policy. Secretary for the Department of Health and Human Services Robert F. Kennedy Jr. announced earlier this year that the COVID-19 shot will no longer be recommended for healthy children and pregnant women. Kennedy also abruptly fired all 17 members of an independent vaccine advisory panel for the Centers for Disease Control and Prevention in June. He then replaced the panel with eight hand-picked appointees, many of whom have expressed vaccine skepticism in the past. Adults who identify as Republicans are far less likely to plan on getting the vaccine compared to those who identify as Democrats. About six out of 10 Republicans said they would 'definitely not' get the shot compared to about one out of 10 Democrats, according to the poll. White adults are the most likely to say that they are against getting the vaccine once the colder months arrive with about four out of 10 admitting they will 'definitely not' get the shot. Meanwhile, 32 percent of Black adults say they will 'definitely not' get the COVID-19 vaccine this fall, along with 30 percent of adults who identify as Hispanic. Adults between the ages of 30 and 49 are the most likely to say that they do not plan on getting the vaccine, with 42 percent of that age group saying they will 'definitely not' get the shot in the fall. The U.S. appears to be experiencing another summer wave of COVID-19 cases. As of July 29, COVID-19 infections are growing or likely growing in 40 states, including Florida, Texas, and New York, according to the CDC. The KFF poll was conducted via a national representative survey of about 1,300 people between July 8-14.
Boston Globe
an hour ago
- Boston Globe
N.H. Governor Kelly Ayotte signs bills banning gender-affirming care for minors
Proponents have said the ban is an important way of protecting children from treatments they believe to be harmful and irreversible. But opponents say the new law discriminates against transgender youth, removing treatments they view as life saving, and interfering with doctors' ability to make appropriate medical decisions with families. Get N.H. Morning Report A weekday newsletter delivering the N.H. news you need to know right to your inbox. Enter Email Sign Up Violations of the new law will go before New Hampshire's board of medicine, which can take administrative disciplinary action. Advertisement The new law also allows someone who was harmed by receiving this care to bring a lawsuit against the person who provided the care and violated the law. The new ban comes as legislative efforts targeting transgender people have grown in recent years. Last year, New Hampshire lawmakers passed a bill banning gender-affirming genital surgeries for minors, even though providers have said such procedures are exceedingly rare in New Hampshire. All of the other New England states have laws protecting access to gender-affirming care, according to the Movement Advancement Project, a Colorado-based think tank that promotes equality. Advertisement Some New Hampshire families with transgender children have been warily watching as the bill advanced and, in some cases, have been Republican lawmakers in New Hampshire who championed the ban were encouraged by a But some attorneys say there are still avenues for pursuing a possible legal challenge of New Hampshire's new law. That could include a challenge based on the New Hampshire constitution, arguing that the intent of the law was to harm transgender people, or a challenge on the basis of parental rights, according to Chris Erchull, a senior staff attorney at GLAD law. Ayotte also signed a second bill banning gender-affirming surgeries for minors. The bill explicitly prohibits 'transgender chest surgery' for minors as part of a gender transition. Violating the law is classified as unprofessional conduct and would be subject to discipline by the board of medicine. The law also allows minors to sue for damages if they received such a treatment in violation of the law. And the attorney general can bring a suit to enforce compliance with the law. Amanda Gokee can be reached at
Fast Company
an hour ago
- Fast Company
A Medicare experiment could change who gets Ozempic
If a new experiment pans out, Medicaid and Medicare could begin covering the costly weight loss drugs that price out many Americans who might want to try them. After killing a Biden-era plan with the same goal, the Trump administration is working on a five-year pilot program that would allow state Medicaid programs and Medicare's prescription plan to opt into covering drugs like Ozempic, Wegovy, Zepbound and Mounjaro for 'weight management,' The Washington Post reports. In its final months, the Biden administration proposed expanding Medicaid and Medicare coverage for popular weight loss drugs, extending it to roughly 7.5 million people enrolled in those programs. In April, the Trump administration tossed that plan – a move that was somewhat expected given Health and Human Services Secretary Robert F. Kennedy Jr.'s vocal opposition to the weight loss drugs that have taken America by storm. Now, something very similar appears to be back on the table. Differences of opinion Kennedy's view is at odds with other members of the Trump administration, including Dr. Mehmet Oz, the administrator of the Centers for Medicare & Medicaid Services (CMS). Oz, a former surgeon best known as a daytime television personality prior to joining the federal government, has long boosted weight loss drugs like Ozempic. 'I'll respect you no matter what your weight might be, but for those who want to lose a few pounds, Ozempic and other semaglutide medications can be a big help,' Oz said in a social media post in 2023. 'We need to make it as easy as possible for people to meet their health goals, period.' Oz has also been paid to promote the drugs in the past. In 2019, Ozempic maker Novo Nordisk sponsored a nine-minute long infomercial on Oz's daytime talk show praising the benefits of using Ozempic for Type 2 diabetes. On the other side of the coin, Kennedy at HHS is staunchly opposed to weight loss drugs like Ozempic and has made misleading claims about the class of drugs in the past. 'They're counting on selling it to Americans because we're so stupid and so addicted to drugs,' Kennedy said in an interview he shared on Instagram last year. Kennedy, a prominent figure in anti-vaccine circles before joining the Trump administration, has a long track record of elevating health conspiracy theories, even while promoting other common sense ideas around health and wellness. Kennedy, who opposes the use of many prescription medications, believes that the prominence of processed foods in the American diet is a root cause of many of the country's health woes. What is the status now? While Medicaid and Medicare don't evenly cover GLP-1 drugs like Ozempic for weight loss, 13 state Medicaid programs do offer coverage to treat obesity. For people on Medicaid and Medicare, coverage is much more widely available when GLP-1 drugs are prescribed to Type 2 diabetes. The Washington Post reports that the trial program is slated to start in April 2026 for Medicaid and in January 2027 for Medicare. The program is connected to the Center for Medicare and Medicaid Innovation, which experiments with new ways to lower costs and deliver coverage for people enrolled in those subsidized insurance programs. According to documents viewed by the Post, the program has yet to be finalized. Whether it goes into effect or not, the experimental plan to extend coverage shows that the anti-Ozempic faction of the Trump administration might find itself overruled when it comes to the weight loss drug.
